MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
International Journal of Gynecological Cancer
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

914 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
914 works in the cohort · of 4,299,418page 9 of 19

Labels cover 3 of 914 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 914 of 914 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Coping With Cancer
Sarah N. Smith, Donna R. Chizen, Anita Agrawal
2014· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, B-G. Kim, Ana Oaknin, Michael Friedländer +15 more
2019· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
#267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial
Dana M. Chase, Line Bjørge, Robert L. Coleman, Oleksandr Zub, Eirwen M. Miller, Roberto Angioli +14 more
2023· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
Ritu Salani, Kristina Lindemann, Zhongqiu Lin, Shin Nishio, Ana Oaknin, Jean‐Emmanuel Kurtz +14 more
2025· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
TP016/#1442 Keynote-C93/GOG-3064/ENGOT-EN15: phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma
Brian M. Slomovitz, David Cibula, Murat Gültekin, Mansoor Raza Mirza, Beata Maćkowiak-Matejczyk, Alexandra A. Taylor +14 more
2022· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Mirvetuximab soravtansine: an oasis in the desert?
Luisa Bonilla, Lawrence Kasherman, Luís Manso, Ainhoa Madariaga
2024· editorial· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
#1121 KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa +11 more
2023· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Gallstone mimicking metastatic cervical cancer
Catherine Pouyez, Meriame Dami
2021· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Resisting RECIST—Uniformity Versus Clinical Validity
Michelle Wilson, Michael Friedländer, Stéphanie Lheureux, William Small, Andrés Poveda, Éric Pujade-Lauraine +5 more
2017· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · metaresearchconsensus · metaresearch
1
citations
affunlabeled
In memorium: C Paul Morrow (1935–2022)
Neville F. Hacker, Peter Heintz, Amodio Denny De Petrillo
2022· letter· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
← previousnext →

How this was built: Screen · Findings · About